A10BJ05 - Dulaglutide |
Propably not porphyrinogenic |
PNP |
Important Information
Nausea and vomiting are reported are very common side effects of dulaglutide that may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Side effects
Nausea and vomiting is reported as very common adverse reactions of dulaglutid especially when used in doses of 1,5 mg weekly (Thompson 2015). These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Dulaglutide is not metabolized by CYP, and is not an inducer or inhibitor of CYP.
Chemical description
Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Therapeutic characteristics
Dulaglutide is indicated in adults with type 2 diabetes mellitus to improve glycaemic control
It is administered once weekly as a subcutaneous injection.
Metabolism and pharmacokinetics
Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways (SPC).
Dulaglutide is not expected to affect the cytochrome P450 system, and no CYP related interactions are listed in drug-drug interaction databases.
References
- Scientific articles
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue). PMID 19934256. #4728
- Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015 Mar;49(3):351-9. PMID 25565404. #3220
- Drug interaction databases
- Lexi-Interact, via UpToDate. #1152
- Micromedex® 2.0 (online). Drug Interactions). (08.12.2016). #3221
- The Danish Health and Medicines Authority. The drug interaction database. #1298
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Trulicity. #3219
- Other sources
- Interaction databases: #3014
Similar drugs
© NAPOS 2024